Trial Profile
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms AWARE
- Sponsors Janssen
- 05 Jun 2021 Results of a post hoc analysis assessing the safety and efficacy of IV GLM and IFX in elderly presented at the 22nd Annual Congress of the European League Against Rheumatism
- 05 Jun 2021 Results assessing the patient reported outcomes of Golimumab and infliximab in patients with rheumatoid arthritis, presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism